your initial deposit *subject to change and depends on individual circumstances.
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the...Read more
Summit Corp to present Alzheimer’s research data at Paris conferenceJuly 19 2011, 9:06am
Drug discovery group Summit Corporation PLC (LON:SUMM) said it is presenting the recently reported positive results from its programme targeting Alzheimer's disease and other neurological disorders at the Alzheimer's Association International Conference 2011 (ICAD 2011) which is currently being held in Paris.
Alzheimer's is a progressive and debilitating neurodegenerative disorder and is the most common form of dementia. It remains an area of high unmet medical need with current treatment options only providing symptomatic relief.
The presentation will highlight Summit's focus on a new and potentially disease modifying strategy for the treatment of Alzheimer's disease that targets the enzyme OGA (O-linked N-acetylglucosaminidase).
The company identifid and then optimised the generation of extremely potent, selective and non-cytotoxic inhibitors of OGA using its Seglin technology drug discovery platform.
Summit will also demonstrate in a human cellular model that the Seglin OGA inhibitors reduce levels of an abnormal form of the protein Tau, found in the brain of Alzheimer's patients and which causes the formation of toxic 'tangles' and ultimately results in disease symptoms.
Interest in the Tau protein as an approach for developing drugs to treat Alzheimer's disease continues to increase as evidenced by the growing number of peer-reviewed scientific publications, Summit said.
“As results from Summit's early-stage programme show, inhibition of OGA by Seglins can reduce the levels of hyperphosphorylated Tau and potentially offers a new strategy for treating this disease,” it added.